oroxylin A 7-butyryl ester

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: oroxylin A 7-butyryl ester
• 英文别名: (5-Hydroxy-6-methoxy-4-oxo-2-phenylchromen-7-yl) butanoate
• 化学式: C₂₀H₁₈O₆
• 分子量: 354.359
• InChiKey: GKJDYYHDRKMDRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  82.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  千层纸素A 、 丁酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 oroxylin A 7-butyryl ester
  参考文献：
  名称：

  Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents

  摘要：

  A series of Oroxylin A derivatives, prepared by alkylation and condensation, were fully characterized by spectroscopic methods. All the derivatives were screened for antibacterial activity against a panel of susceptible and resistant Gram-positive and Gram-negative organisms. It was observed that acylation of 7-OH group in Oroxylin A significantly enhanced the activity as compared to their parent compound (Oroxylin A).

  DOI：

  10.1016/j.bmcl.2005.05.045

文献信息

• 千层纸素A及其前体药物作为儿茶酚类药物增效剂的应用
  申请人：中国科学院大连化学物理研究所

  公开号：CN105315251A

  公开（公告）日：2016-02-10

  一种千层纸素A及其前体药物作为儿茶酚类药物增效剂的应用属医药技术领域。该类化合物作为儿茶酚类药物增效剂，具有如下结构通式如(1)所示，其中，R为氢、羧酸酯及葡萄糖醛酸等取代基。上述千层纸素A及其前体药物中的一种或几种化合物均可与左旋多巴按一定比例混合后做成药物组合物并用于帕金森病的治疗，千层纸素A及其改造后的前体药物溶解度和透膜能力都得到改善，同时其体内代谢半衰期明显延长，超过多数儿茶酚类药物的体内半衰期，具有良好的成药前景。此外，该类化合物还可与儿茶酚类药物组成复方药物，并可采用口服缓释剂型进一步提升儿茶酚类药物的口服生物利用度及治疗效果。
• Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents
  作者：K. Suresh Babu、T. Hari Babu、P.V. Srinivas、B.S. Sastry、K. Hara Kishore、U.S.N. Murty、J. Madhusudana Rao

  DOI：10.1016/j.bmcl.2005.05.045

  日期：2005.9

  A series of Oroxylin A derivatives, prepared by alkylation and condensation, were fully characterized by spectroscopic methods. All the derivatives were screened for antibacterial activity against a panel of susceptible and resistant Gram-positive and Gram-negative organisms. It was observed that acylation of 7-OH group in Oroxylin A significantly enhanced the activity as compared to their parent compound (Oroxylin A).